Neutralizing antibodies (e.g., FLO1 mAb) could disrupt IL-1α-driven barrier dysfunction while promoting probiotic enrichment (52), as evidenced by reduced ileitis/colitis severity upon blockade. Here, IL1A is linked to colitis.